utic option for refractory epilepsy. International journal of clinical practice 57,616 - 21.
[0377] 9 Muller CA, Schafer Mj Schneider S，Heimann HMj Hinzpeter A, Volkmar Kj Forg AjHeinz A & Hein J(2010)Efficacy and safety of levetiracetam for outpatient alcohol detoxification. Pharmacopsychiatry 43,184 - 9.
[0378] 10 Kondoh T，Kanno A， Itoh H，Nakashima M，Honda R，Kojima M，Noguchi M，Nakane H，Nozaki H，Sasaki H，Nagai T，Kosaki R，Kakee N，Okuyama T，Fukuda M，Ikeda M，Shibata Y & Moriuchi H(2011)Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment:a 24-week randomized, double-blind, placebo-controlled trial. International journal of psychiatry in medicine 41,71 - 89.
[0379] 11 Stackman RW & Walsh TJ(1994)Baclofen produces dose-related working memory impairments after intraseptal injection. Behavioral and neural biology 61，181 - 5.
[0380] 12 Grande LAjLoeser JD & Samii A(2008)Recurrent transient global amnesia with intrathecal baclofen. Anesthesia and analgesia 106, 1284 - 7, table of contents.
[0381] 13 Schneider UjWohlfarth KjSchulze-Bonhage AjHaacker TjMliller-Vahl KR, Zedler M，Becker H，Dengler R & Emrich HM (1999) Effects of acamprosate on memory in healthy young subjects. Journal of studies on alcohol60,172 - 5.
[0382] 14 Tannenbaum C，Paquette A，Hilmer S，Holroyd-Leduc J & Carnahan R(2012) A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine,GABAergic and opioid drugs.Drugs & aging 29, 639 - 58.
[0383] 15 Ettmayer PjAmidon GLjClement B & Testa B (2004) Lessons learned from marketed and investigational prodrugs. Journal of medicinal chemistry 47, 2393 - 404.
[0384] 16 Beaumont K，Webster R，Gardner I & Dack K (2003) Design of ester prodrugs to enhance oral absorption of poorly permeable compounds:challenges to the discovery scientist. Current drug metabolism 4, 461 - 85.
[0385] 17 Heimbach TjOh DMjLi LYjRodrlguez-Hornedo NjGarcia G & Fleisher D(2003)Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. International journal of pharmaceutics 261, 81 - 92.
[0386] 18 Yang CYjDantzig AH & Pidgeon C(1999)Intestinal peptide transport systems and oral drug availability. Pharmaceutical researchl6, 1331 - 43.
[0387] 19 Steffansen B，Nielsen CU, Brodin B，Eriksson AH，Andersen R &Frokjaer S(2004)Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption.European journal of pharmaceutical sciences!official journal of the European Federation for Pharmaceutical Sciences 21, 3 - 16.
[0388] 20 Stella VJ(2007)Prodrugs:challenges and rewards. Springer Singapore Pte. Limited.
[0389] 21 Wermuth CG(2011)The Practice of Medicinal Chemistry Elsevier Science.
[0390] 22 Pezron IjMitra AKjDuvvuri S & Tirucherai GS (2002) Prodrug strategies in nasal drug delivery. Expert Opinion on Therapeutic Patents 12, 331 - 340.
[0391] 23 Stella VJ(2004)Prodrugs as therapeutics.Expert Opinion on Therapeutic Patents 14, 277 - 280.
[0392] 24 Stella VJ & Nti-Addae KW(2007)Prodrug strategies to overcome poor water solubility. Advanced drug delivery reviews 59,677 - 94.
[0393] 25 Roche EB(1977)Design of biopharmaceutical properties through prodrugs and analogs:a symposium，American P The Academy，Washington，DC.
[0394] 26 Lal RjSukbuntherng JjTai EHLjUpadhyay SjYao FjWarren MSjLuo WjBu Lj Nguyen S，Zamora J，Peng G，Dias T，Bao Yj Ludwikow M，Phan T，Scheuerman RA, Yan HjGao MjWu QQjAnnamalai TjRaillard SPjKoller KjGallop MA & Cundy KC(2009) Arbaclofen placarbil，a novel R-baclofen prodrug:improved absorption, distributi on, metabolism, and elimination properties compared with R-baclofen.The Journal of pharmacology and experimental therapeutics 330,911 - 21.
[0395] 27 Xu F，Peng G，Phan T，Di I ip U，Chen 几，Chernov-Rogan T，Zhang X，Grindstaff K，Annamalai TjKoller KjGallop MA & Wustrow DJ(2011)Discovery of a novel potent GABA(B)receptor agonist. Bioorganic & medicinal chemistry letters 21,6582 - 5.
[0396] 28 Leach AR & Gillet VJ An Introduction to Chemoinformatics(Springer-V erlag New York Incj ed.).
[0397] 29 Rahman SA，Bashton M，Holliday GL，Schrader R & Thornton JM(2009)Small Molecule Subgraph Detector (SMSD) toolkit. Journal of cheminformaticsl, 12.
[0398] 30 Stahl PH & Wermuth CG(2008)Pharmaceutical Salts Wiley.
[0399] 31 Hanafi R，Mosad S，Abouzid K，Niess R & Spahn-Langguth H(2011) Baclofen ester and carbamate prodrug candidates:a simultaneous chromatographic assay, resolution optimized with DryLab. Journal of pharmaceutical and biomedical analysis 56,569 - 76.
[0400] 32 DEMBER WN & FOWLER H(1958)Spontaneous alternation behavior. Psychological bulletin 55,412 - 28.
[0401] 33 De Bruin NMWJjPrickaerts JjLange JHMjAkkerman SjAndriambeloson EjDe Haan Mj Wijnen J，Van Drimmelen M，Hissink E，Heijink L & Kruse CG(2010)SLV330,a cannabinoid CBl receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. Neurobiology of learning and memory 93, 522 - 31.
[0402] 34 Snyder PJjBednar MMjCromer JR & Maruff P (2005) Reversal of scopolamine-induced deficits with a single dose of donepeziI, an acetylcholinesterase inhibitor. Alzheimer' s & dementia:the journal of the Alzheimer's Association I,126 - 35.
【主权项】
1. 组合物在健康受试者中刺激认知功能的用途，所述组合物包含选自以下的至少两种 药物的组合：巴氯芬、阿坎酸、西那卡塞、美西律、磺胺异噁唑和托拉塞米，或它们中的一种 或多种盐、一种或多种前药、一种或多种衍生物或一种或多种持续释放制剂。2. 权利要求1的用途，其中所述认知功能选自记忆、学习、推理、警戒、注意力、集中力、 语言加工和/或应付社会职业负担的能力。3. 权利要求2的用途，其中所述记忆为短时程记忆和/或长时程记忆。4. 前述权利要求中任一项的用途，其中所述组合物包含选自以下的药物的组合： -巴氯芬和阿坎酸， -美西律和西那卡塞， -巴氯芬和托拉塞米，或 -磺胺异噁挫和托拉塞米。5. 前述权利要求中任一项的用途，其中所述组合物包含巴氯芬和阿坎酸的组合。6. 权利要求5的用途，其中所述组合物包含巴氯芬和阿坎酸作为仅有的活性剂。7. 前述权利要求中任一项的用途，其中所述组合物还包含药学上可接受的载体或赋形 剂。8. 前述权利要求中任一项的用途，其中在所述组合物中的药物一起、分开或依次配制 或给药。9. 前述权利要求中任一项的用途，其中将所述组合物重复给药于所述受试者。10. 权利要求1-9中任一项的用途，其中所述健康受试者需要记忆、学习或警戒表现的 短暂刺激。11. 权利要求1-9中任一项的用途，其中所述健康受试者显示出由激素变化或失调引 起的短暂记忆丧失，如在怀孕时、产后、在围绝经期或绝经期。12. 权利要求1或4-9中任一项的组合物，其用于在暴露于对记忆具有潜在的负面影响 的治疗或给药方案的受试者中或面临暴露于所述治疗或给药方案风险的受试者中治疗记 忆和/或记忆相关的心理功能受损，所述治疗或给药方案例如毒性试剂、药物戒断或饮食 缺陷。13. 权利要求1或4-9中任一项的组合物，其用于在正在遭受或已经遭受学习、语言、计 算和/或阅读困难例如，计算障碍，工整书写困难或诵读困难的受试者中或在面临遭受所 述困难的风险的受试者中治疗所述困难。14. 权利要求1或4-9中任一项的组合物，其用于正在遭受或已经遭受精神障碍、智力 低下或甲状腺功能减退的受试者中或在面临遭受精神障碍、智力低下或甲状腺功能减退的 风险的受试者中治疗记忆和/或记忆相关的心理功能受损。15. 用于权利要求14的用途的组合物，其中所述智力低下选自鲁宾斯坦-泰比综合征、 格雷格综合征、阿佩尔综合征、安格尔曼综合征、科-勒二氏综合征、雷特氏综合征、脆性X 综合征或威廉氏综合征。16. 用于权利要求14的用途的组合物，其中所述精神障碍选自抑郁症、精神障碍、注意 力缺陷多动障碍、焦虑症或强迫症。17. 用于权利要求12的用途的组合物，其中所述毒性试剂选自重金属、苯二氮,草类、巴 比妥类、抗惊厥剂、第一代抗组胺能药物、抗胆碱能药、他汀类药物和麻醉剂。18. 用于权利要求12-17中任一项的用途的组合物，其中记忆为短时程记忆和/或长时 程记忆。19. 用于权利要求12-17中任一项的用途的组合物，其中记忆相关的心理功能为学习、 推理、警戒、注意力、集中力、语言加工和/或应付社会职业负担的能力。
【专利摘要】本发明涉及用于改善记忆和相关功能如警戒、注意力、集中力、学习和语言加工的组合物和方法。更具体地，本发明涉及包含选自西那卡塞、巴氯芬、阿坎酸、美西律、磺胺异噁唑和托拉塞米中的至少两种药物的组合物，其用于在健康受试者中或罹患对记忆具有负面影响的病症或障碍的患者中增强记忆和相关功能。
【IPC分类】A61P43/00, A61P25/16, A61K31/635, A61P25/18, A61P39/02, A61K31/135, A61P25/24, A61K31/44, A61K31/195, A61K31/137, A61K31/185, A61P25/00, A61P25/36
【公开号】CN104884053
【申请号】CN201380052487
【发明人】D.科恩, S.纳比罗克金, I.查马科夫
【申请人】法奈克斯公司
【公开日】2015年9月2日
【申请日】2013年9月4日
【公告号】CA2883691A1, EP2705841A1, EP2892519A1, US20150224092, WO2014037412A1